How to search FDA 503B outsourcing-facility product reports

01

What a 503B product report records

An outsourcing facility that registers under section 503B must report certain information about drugs it compounded. FDA’s procedure page says reports are due at initial registration and during June and December for products produced in the preceding six-month period.

FDA makes recent information available through the Outsourcing Facility Product Report searchable database. Its information page says the database contains the last two years, or four reporting periods, and may help identify facilities that produced particular drugs.

The record answers a narrow historical question: what did this facility report producing in this period? It does not answer whether a patient should use the drug, whether it was prescribed or administered, or whether it remains available.

02

Start with the exact product identity

Write down the nonproprietary ingredient name, dosage form, route, strength or concentration, and any salt or ester. Search close variants only after the exact search because naming differences can create false misses or false matches.

A product name can conceal important differences. Semaglutide injection and an oral product are not the same record; a single-ingredient product and a combination are not interchangeable; free-base and salt forms may raise different questions.

Save the result page, reporting period, facility name, and date checked. If the result does not match the label or provider’s statement, ask for clarification rather than assuming fraud or equivalence.

• →Exact ingredient and chemical form
• →Dosage form and route
• →Strength or concentration
• →Combination ingredients
• →Facility legal name and location
• →Reporting period

03

Cross-check the current registration record

Open FDA’s Registered Outsourcing Facilities table and match the legal name and location. The table shows initial and recent registration dates and may display the last inspection, whether a Form 483 was issued, whether a recall was conducted, and the action based on the last inspection.

Registration is annual and voluntary. FDA’s registration Q&A explains the information and fee process, while the public table is based on a complete registration submission. Registration does not approve the facility’s compounded drugs.

A facility can be registered but not yet inspected. An inspection can produce an open Form 483 or later action. Treat these as separate dated fields and follow the linked documents before drawing a conclusion.

04

Understand reporting windows and missing records

Reports filed in June cover products compounded from December 1 through May 31. Reports filed in December cover June 1 through November 30. A new or recently changed product may not appear until the applicable filing window, and the public search focuses on recent periods.

A missing result does not prove no product was ever made, that a 503A pharmacy did not dispense it, or that a facility violated reporting rules. The database concerns registered outsourcing facilities and displayed periods. Spelling, identity, timing, and updates can also matter.

Conversely, an older match does not prove current production or availability. Ask the provider or facility for current, product-specific information and preserve the date of the answer.

FDA’s reporting guidance describes structured product information rather than a consumer inventory feed. A facility can report that it compounded a product during a covered period without promising that the product is in stock, available to a particular clinic, or eligible for every patient. Treat the database as a research lead that needs current confirmation.

05

What a report cannot prove about quality or legality

Product reporting is not premarket approval. Compounded drugs made by outsourcing facilities are not FDA-approved, and FDA does not evaluate each reported product for safety, effectiveness, and quality before it appears in the database.

A report also does not prove the facility satisfied every 503B condition, that the ingredient was eligible, that copy restrictions were met, that a lot passed all testing, or that shipping and storage were appropriate. Those questions require other records.

Do not use a match as a 503B-certified, FDA-verified, or FDA-approved badge. Accurate wording is that the named facility reported compounding the identified product during the stated period.

06

Connect a clinic claim to the actual supply chain

A consumer-facing platform may contract with a medical group, which sends a prescription or order through a dispensing pharmacy or outsourcing facility. The package may name another central-fill or fulfillment organization. Identify each legal entity and role instead of attributing every step to the website brand.

Compare the product label and shipping documents with the product report and registration table. Ask which facility compounded the patient’s lot and whether that facility appears in the report for the matching product and period. A partnership announcement is not lot-level evidence.

If records conflict, contact the dispensing pharmacy before using the product. For a suspected quality problem, preserve photographs, the full label, lot, beyond-use date, packaging, temperature evidence, and correspondence. Product decisions require an appropriately licensed clinician and pharmacist.

Document negative findings carefully. “No match found in the last four reporting periods under this spelling” is more accurate than “the facility never made this drug.” That wording preserves the database’s scope and gives the facility or pharmacy a fair opportunity to identify a different name, period, location, or source record.